(Oslo, June 4th, 2014) Immunotherapy specialist Targovax today announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed.
CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company”.
Chairman Jonas Einarsson comments; “This is an important step forward for Targovax, and clearly shows that the Norwegian investment community has opened its eyes to our sector.”
Datum and partners represent the largest new group of shareholders, and look forward to working together with the company management in the years to come, to develop the company’s potential.
Arctic Securities ASA is the manager for the share issue. The company will be OTC-listed shortly after completion of the financing round.